Friday, December 16, 2022 9:42:53 AM
targets range from 8-15
Recent CMPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 12:32:02 PM
- Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Compass Therapeutics Announces CEO Transition • GlobeNewswire Inc. • 05/28/2024 08:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:09:10 PM
- Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meet • GlobeNewswire Inc. • 05/23/2024 09:05:00 PM
- Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:00:36 PM
- Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference • GlobeNewswire Inc. • 04/12/2024 12:00:00 PM
- Compass Therapeutics to Participate in the Stifel Targeted Oncology Days • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/09/2024 04:00:00 PM
- Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/21/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:12:03 PM
- Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 05:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 05:50:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 03:31:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 01:00:18 PM
- Compass Therapeutics Provides Corporate Update • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:10:51 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM